Literature DB >> 28858074

Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.

Kayci Huff-Hardy1, Mai Bedair, Rebecca Vazquez, Ezra Burstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28858074     DOI： 10.1097/MIB.0000000000001232

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  5 in total

Review 1.  Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic.

Authors:  Nicole Lopez; Sonia Ramamoorthy; Willam J Sandborn
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-04-26       Impact factor: 3.869

Review 2.  Unmet needs in inflammatory bowel disease.

Authors:  Joana Revés; Ryan C Ungaro; Joana Torres
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-11-30

Review 3.  Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature.

Authors:  Magdalena Wlazło; Jarosław Kierkuś
Journal:  J Clin Med       Date:  2022-04-03       Impact factor: 4.241

Review 4.  Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.

Authors:  Christine Olbjørn; Jon Bergreen Rove; Jørgen Jahnsen
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022

Review 5.  A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.

Authors:  Hang Hock Shim; Pak Wo Chan; Sai Wei Chuah; Brian J Schwender; San Choon Kong; Khoon Lin Ling
Journal:  JGH Open       Date:  2018-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.